ONVO—Other FXR agonists for NASH (most notably ICPT’s Ocaliva) have failed due to pruritis and/or liver toxicity, so ONCO’s FXR314’s low rate of pruritis at the tested doses is what stands out. The question is whether the drug has enough efficacy at these doses to do more than merely reduce liver fat.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.